Convatec welcomes regulatory approval of subcutaneous apomorphine infusion for advanced Parkinson’s disease in the US

- Parkinson’s is the second-most common neurodegenerative disorder in the US and has a rising incident rate (Parkinson’s Foundation)²
- Regulatory approval of new drug applications will give patients more options for treatment and care of advanced Parkinson’s disease in the United States¹
- Convatec’s Neria™ Guard infusion set is used for continuous subcutaneous infusion of a wide range of pharmaceuticals in the United States.³ Neria™ Guard is indicated for continuous subcutaneous infusion of medication administered by an external pump³

London, UK, 26 June 2025 – Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, welcomes approval from the US Food and Drug Administration (FDA) of apomorphine hydrochloride for subcutaneous infusion for the treatment of advanced Parkinson’s disease¹.
 
An estimated 1 million people in the US are living with Parkinson's disease, a number that is expected to increase to 1.2 million by 2030, according to the Parkinson’s Foundation².

FDA approval ensures healthcare providers will have access to a new treatment to address motor fluctuations and improve ‘on’ time for the growing number of patients living with Parkinson’s disease. Apomorphine is delivered under-the-skin (subcutaneous) as a continuous infusion via a small portable infusion pump and Convatec’s Neria™ Guard infusion set without the need for an invasive surgical procedure. The Neria™ Guard insertion technology is designed for ease and simplicity, with one touch button that protects against human error and improves patient independence^3,4.

Convatec is the global leader in infusion set design, development and manufacturing for subcutaneous drug delivery. The Convatec Neria™ Guard infusion set, launched in 2017, is already widely used for Parkinsons’ disease treatment in Europe and the use with apomorphine will now be expanded through our partners to include US¹ patients. 

Parkinson's disease is the second-most common neurodegenerative disorder in the US with more than 1 million people affected². Newly published data on the increase in the incidence rate at nearly 90,000 new cases per year compared to the previous 60,000 cases annually in the US⁵ demonstrates the importance of new treatment options for healthcare professionals and their patients.

Kjersti Grimsrud, President & Chief Operating Officer, Infusion Care at Convatec said: “Patients already know how user friendly our Neria™ Guard is and now with this new US FDA approval, we’re able to expand its use to include apomorphine treatment in US, following its success in Europe. Having new treatment options is a big win for Parkinson’s patients and their families, and we are very pleased that we can help give more independence to people to live their daily lives.”

Convatec delivers approximately 130 million products every year⁶ to serve end users in disease areas such as diabetes, Parkinson’s disease, pain management, and primary immunodeficiency³. More than 1 million people around the world use Convatec infusion sets every day.⁶ 

About Neria™ Guard
Neria™ Guard is an all-in-one infusion set with fully automatic insertion at the touch of a button³. The infusion set connects to a pump on one end and the user’s body on the other end, to deliver medication into the subcutaneous tissue continuously. The retractable needle can provide increased comfort* during the insertion of the small soft cannula situated in the skin and can help prevent accidental needle-stick incidents³. Neria™ Guard's easy and intuitive insertion technique³ protects against user errors³ and may help support use at home and encourage independence in patients’ everyday lives.^3,4 Convatec Neria™ Guard infusion set is indicated for subcutaneous infusion of medication³. Neria™ Guard is indicated for continuous subcutaneous infusion of medication administrated by an external pump³. For information about Neria™ Guard, please refer to the instructions for use that come with the product. An explainer video is available here.

*Compared to a steel needle. 

Contacts

Analysts & Investors: ir@convatec.com

Media: mediarelations@convatec.com

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

References

1. Second Under-the-Skin Infusion for Parkinson’s Earns FDA Approval | Parkinson's Disease, accessed 20-06-2025
2. Statistics | Parkinson's Foundation, accessed 20-06-2025
3. Convatec Data on File, Unomedical A/S. (D012-002912), 20.1.2023
4. Elizabeth Hillman. Examining the use of sharp-free subcutaneous infusion devices with apomorphine. British Journal of Neuroscience Nursing, August/September 2020 Vol 16 No 4
5. Prevalence & Incidence _ Parkinson_s Foundation, accessed 20-06-2025
6. Convatec Data on file, Sales data, 2024

AP-75453- GBL-ENG-v1